Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Increases By 816.4%

Posted by Stanley Muller on Jul 11th, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 91,267 shares, a growth of 816.4% from the June 15th total of 9,959 shares. Based on an average trading volume of 194,642 shares, the short-interest ratio is presently 0.5 days. Approximately 2.5% of the shares of the company are short sold.

Institutional Investors Weigh In On Pulmatrix

A hedge fund recently bought a new position in Pulmatrix stock. Dimensional Fund Advisors LP acquired a new stake in Pulmatrix, Inc. (NASDAQ:PULM – Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned 0.30% of Pulmatrix at the end of the most recent quarter. Hedge funds and other institutional investors own 11.84% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulmatrix in a research note on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Pulmatrix has a consensus rating of “Sell”.

View Our Latest Stock Report on PULM

Pulmatrix Price Performance

Shares of NASDAQ:PULM traded down $0.08 during trading on Friday, hitting $1.72. 46,122 shares of the company were exchanged, compared to its average volume of 109,360. Pulmatrix has a 52-week low of $1.16 and a 52-week high of $6.83. The stock has a 50 day moving average of $1.45 and a 200 day moving average of $1.89. The company has a market cap of $6.28 million, a PE ratio of -1.40 and a beta of 1.90.

Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings results on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share for the quarter.

Pulmatrix Company Profile

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).